← All trials
NCT05157711
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Dec 15, 2021
- Last posted
- Dec 15, 2021
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Church & Dwight Company, Inc.Lead sponsor
- Church & Dwight Company, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.